Kenny John P.'s Form 4 filing
Meridian Bioscience Inc · filed Jun 24, 2022
- Accession no.
- 0001127602-22-018097
- Filed
- Jun 24, 2022
- Trade date
- Jun 22-23, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.93M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kenny John P.CIK 0001719325 | Director, Officer (Chief Executive Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 22, 2022 | Common Stock | MOption exerciseAcquired | +44,651 | $14.50 | +$647,439.5 | 309,782 | Direct | |
| Jun 22, 2022 | Common Stock | SSaleDisposed | −44,651 | $29.72F2 | −$1,327,027.72 | 265,131 | Direct | |
| Jun 23, 2022 | Common Stock | MOption exerciseAcquired | +5,349 | $14.50 | +$77,560.5 | 270,480 | Direct | |
| Jun 23, 2022 | Common Stock | MOption exerciseAcquired | +14,607 | $10.10 | +$147,530.7 | 285,087 | Direct | |
| Jun 23, 2022 | Common Stock | SSaleDisposed | −19,956 | $29.98F4 | −$598,280.88 | 265,131 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 22, 2022 | Common Stock | MOption exerciseDisposed | −44,651 | $0.00 | $0 | 5,349 | Direct | |
| Jun 23, 2022 | Common Stock | MOption exerciseDisposed | −5,349 | $0.00 | $0 | 0 | Direct | |
| Jun 23, 2022 | Common Stock | MOption exerciseDisposed | −14,607 | $0.00 | $0 | 141,035 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $29.50 to $29.94. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
Referenced by the price of 1 transaction in Table I.
- F4
The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $29.61 to $30.13. The Reporting Person undertakes to provide full pricing information if requested by the Securities and Exchange Commission, the issuer or a security holder of the issuer.
Referenced by the price of 1 transaction in Table I.